Targeted therapy of colorectal cancer – state of the art

Beata Utracka-Hutka

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2006
vol. 10

Send email

Copy url:

abstract:

Targeted therapy of colorectal cancer – state of the art

Beata Utracka-Hutka

Współcz Onkol (2006) vol. 10; 3 (121-127)

Online publish date: 2006/04/12

View full text Get citation

The recent development of drugs that target the key components of biologic pathways rendered an improvement in survival in colorectal cancer patients. Two monoclonal antibodies in particular, targeting vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) – bevacizumab and cetuximab are clinically available. The expectations with low molecular weight tyrosine kinase inhibitors in the treatment of colorectal cancer have not been confirmed. This review focuses on the defining role of the novel targeted agents in colorectal cancer.

keywords:

Targeted therapy of colorectal cancer – state of the art

Beata Utracka-Hutka

Colorectal cancer, targeted therapy, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF)